Jenny Lee
University of California, San Francisco · 270 works · 5,786 citations · h-index 35
Top works
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
- Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
- Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies
- Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
- Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma
- Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
- Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
- Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
- Evaluation of commercial kits for purification of circulating free DNA
- The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
- Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors
- Liquid biomarkers in melanoma: detection and discovery
- Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors
- Lesion-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma (MM).
- Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia
- Metastasis‐specific patterns of response and progression with anti‐ PD ‐1 treatment in metastatic melanoma
- Microscope in modern spinal surgery: advantages, ergonomics and limitations
- Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
- Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients